Published Date: 10 Mar 2023
China: A recent study by BMC Medicine has shown that the amount of insoluble fiber from various foods plays an important role...
Read Full News(This Aug 27 story has been republished, with no changes to text.)
Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.
After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.
Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.
Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.
1.
I Was Told I Had 6 Months to Live. That Was 20 Years Ago.
2.
Glofitamab Regimen Improves Survival in DLBCL
3.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
4.
Sarah Ferguson was identified as having malignant melanoma. These are the most recent therapies.
5.
Gatekeeping May Reduce Pediatric Cancer Trial Participation
1.
What is Mullerian and How Does it Affect Your Health
2.
Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications
3.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
4.
Emerging Models in Oncology for Specialists
5.
AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
2.
Navigating the Complexities of Ph Negative ALL - Part V
3.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation